PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Lead To Decisive Management and Treatment Decisions in Prostate Cancer
Weksler, M.; Simon, A.; Lenkinski, R.E.; Landsman, H.; Matzkin, H.; Mabjeesh, N.; Leibovitch, I. A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer. Diagnostics2023, 13, 424.
Weksler, M.; Simon, A.; Lenkinski, R.E.; Landsman, H.; Matzkin, H.; Mabjeesh, N.; Leibovitch, I. A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer. Diagnostics 2023, 13, 424.
Weksler, M.; Simon, A.; Lenkinski, R.E.; Landsman, H.; Matzkin, H.; Mabjeesh, N.; Leibovitch, I. A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer. Diagnostics2023, 13, 424.
Weksler, M.; Simon, A.; Lenkinski, R.E.; Landsman, H.; Matzkin, H.; Mabjeesh, N.; Leibovitch, I. A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer. Diagnostics 2023, 13, 424.
Abstract
A key step in providing management/treatment options to men with suspected prostate cancer (PCa) is categorizing the risk for the presence of benign, low risk, intermediate risk, or high-risk disease. Our novel modality brings new evidence, based on the long-known hallmark characteristic of PCa – decreased Zinc (Zn), which is the most direct metabolic sign of malignancy and its aggressiveness. To date, this approach has not been adopted for clinical use for a number of reasons that are described in this article and which have been addressed by our approach: Zn has to be measured on fresh samples, prior to fixating in formalin, therefore samples have to be scanned during the biopsy session; as Zn depletion occurs in the glands, where the tumors develop, estimation of the glands’ levels in the scanned tissue along with their compactness, are essential for accurate diagnosis. Combined with the Zn depletion, this facilitates a reliable assessment of the disease aggressiveness. Data gathered in the clinical study described here indicate that in addition to improving the biopsy quality by real-time interactive guidance, a malignancy score can now be established for the entire prostate, allowing higher granularity personalized risk stratification and more decisive treatment decisions for all PCa patients.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
